Showing results (41-50 of 71) with videos related to
Sort By:
Pageof 8
Oncology Reports|April 9, 2013
Combretazet-3 a novel synthetic cis-stable combretastatin A-4-azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancerLisa M Greene, Shu Wang, Niamh M O'Boyle, et al.Pharmaceuticals (Basel, Switzerland)|January 23, 2020
Design, Synthesis and Biochemical Evaluation of Novel Ethanoanthracenes and Related Compounds to Target Burkitt's LymphomaAndrew J Byrne, Sandra A Bright, James P McKeown, et al.Journal of Enzyme Inhibition and Medicinal Chemistry|March 13, 2010
Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effectsIrene Barrett, Miriam Carr, Niamh O'Boyle, et al.Journal of Medicinal Chemistry|January 28, 2012
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancerLaura Caboni, Gemma K Kinsella, Fernando Blanco, et al.Pharmaceuticals (Basel, Switzerland)|January 25, 2025
(<i>E</i>)-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3,4,5-Trimethoxyphenyl)allyl)-1<i>H</i>-1,2,4-Triazole and Related Compounds: Their Synthesis and Biological Evaluation as Novel Antimitotic Agents Targeting Breast CancerGloria Ana, Azizah M Malebari, Sara Noorani, et al.Journal of Medicinal Chemistry|November 18, 2010
Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agentsNiamh M O'Boyle, Miriam Carr, Lisa M Greene, et al.Bioorganic & Medicinal Chemistry|October 7, 2008
Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulatorsIrene Barrett, Mary J Meegan, Rosario B Hughes, et al.Journal of Medicinal Chemistry|April 1, 2009
Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulinAndrew J S Knox, Trevor Price, Michal Pawlak, et al.European Journal of Medicinal Chemistry|March 4, 2017
β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cellsAzizah M Malebari, Lisa M Greene, Seema M Nathwani, et al.Bioorganic & Medicinal Chemistry|January 14, 2011
Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agentsYvonne M McNamara, Suzanne M Cloonan, Andrew J S Knox, et al.Pageof 8